NCT04746339

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 411 (actual)
• Sponsor: Brazilian Clinical Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.

Detailed description

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis. Randomization 1:1 - Group 1 will receive Apixaban 2.5mg twice daily vs. matching placebo (Group 2) for 30 days. Primary Objective: To evaluate the clinical impact of a strategy of oral anticoagulation with apixaban comparing with placebo on the number of days alive and out of the hospital/emergency department (DAOH) through 30 days in outpatients with symptomatic SARS-CoV2 infection and risk factors for thrombosis.

Conditions

• Covid19
• Thrombosis

Interventions

Type	Name	Description
DRUG	Apixaban 2.5 MG	Apixaban 2.5mg twice daily for 30 days
DRUG	Placebo	placebo twice daily for 30 days

Timeline

• Start date: 2021-03-04
• Primary completion: 2022-05-13
• Completion: 2022-05-30
• First posted: 2021-02-09
• Last updated: 2022-08-25

Locations

4 sites across 1 country: Brazil